Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), Revolution Medicines (RVMD)

Tipranks - Tipranks - Tue Apr 21, 5:46AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiff Oncology (CRDF), Revolution Medicines (RVMD) and Legend Biotech (LEGN) with bullish sentiments.

Claim 30% Off TipRanks

Cardiff Oncology (CRDF)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Cardiff Oncology today and set a price target of $10.00. The company’s shares closed last Friday at $1.80.

According to TipRanks.com, Burns is a 5-star analyst with an average return of 24.7% and a 51.9% success rate. Burns covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Perspective Therapeutics, and ArriVent BioPharma, Inc. ;'>

Currently, the analyst consensus on Cardiff Oncology is a Strong Buy with an average price target of $9.33.

See Insiders’ Hot Stocks on TipRanks >>

Revolution Medicines (RVMD)

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Revolution Medicines today and set a price target of $170.00. The company’s shares closed last Friday at $148.63.

According to TipRanks.com, Stranahan is a 5-star analyst with an average return of 11.6% and a 54.9% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Recursion Pharmaceuticals, and Crispr Therapeutics AG. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $161.24 average price target, a 7.9% upside from current levels. In a report issued on April 6, LifeSci Capital also maintained a Buy rating on the stock with a $144.00 price target.

Legend Biotech (LEGN)

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech, with a price target of $50.00. The company’s shares closed last Friday at $21.17.

According to TipRanks.com, Kapoor is a 5-star analyst with an average return of 15.7% and a 46.2% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Kyverna Therapeutics, Inc., BioMarin Pharmaceutical, and Crispr Therapeutics AG. ;'>

Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $53.73, representing a 153.3% upside. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $62.00 price target.

Read More on CRDF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).